Common use of Study Period Clause in Contracts

Study Period. ‌ The study period for each subject will begin when written informed consent is provided and will continue until Week 56 or early termination is completed. Sites should link the scheduling of visits to the baseline/randomization visit (Visit 2, Day 0). Visit windows are provided to allow subject and site scheduling convenience. However, every effort should be made to ensure that visits occur within these windows so that the overall treatment duration is 56 weeks for subjects who complete all visits. In certain instances, adverse event information may be required for events occurring after the study period (Section 11.3).

Appears in 1 contract

Sources: Investigator Agreement

Study Period. The study period for each subject will begin when written informed consent is provided and will continue until Week Visit 17 (week 56 or early termination termination) is completed. Sites should link the scheduling of visits to the baseline/randomization visit (Visit 2, Day 0). Visit windows are provided to allow subject and site scheduling convenience. However, every effort should be made to ensure that visits occur within these windows so that the overall treatment duration is 56 weeks weeks, including titration period, for subjects who complete all visits. In certain instances, adverse event information may be required for events occurring after the study period (Section 11.38.4).

Appears in 1 contract

Sources: Master Services Agreement (Vivus Inc)

Study Period. The study period for each subject will begin when written informed consent is provided and will continue until Week Visit 17 (week 56 or early termination termination) is completed. Sites should link the scheduling of visits to the baseline/randomization visit (Visit 2, Day week 0). Visit windows are provided to allow subject and site scheduling convenience. However, every effort should be made to ensure that visits occur within these windows so that the overall treatment duration is 56 weeks weeks, including titration period, for subjects who complete all visits. In certain instances, adverse event information may be required for events occurring after the study period (Section 11.38.4).

Appears in 1 contract

Sources: Master Services Agreement (Vivus Inc)